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Abstract
Prion diseases are transmissible neurodegenerative diseases affecting humans and animals. The agent of the disease is the
prion consisting mainly, if not solely, of a misfolded and aggregated isoform of the host-encoded prion protein (PrP).
Transmission of prions can occur naturally but also accidentally, e.g. by blood transfusion, which has raised serious concerns
about blood product safety and emphasized the need for a reliable diagnostic test. In this report we present a method
based on surface-FIDA (fluorescence intensity distribution analysis), that exploits the high state of molecular aggregation of
PrP as an unequivocal diagnostic marker of the disease, and show that it can detect infection in blood. To prepare PrP
aggregates from blood plasma we introduced a detergent and lipase treatment to separate PrP from blood lipophilic
components. Prion protein aggregates were subsequently precipitated by phosphotungstic acid, immobilized on a glass
surface by covalently bound capture antibodies, and finally labeled with fluorescent antibody probes. Individual PrP
aggregates were visualized by laser scanning microscopy where signal intensity was proportional to aggregate size. After
signal processing to remove the background from low fluorescence particles, fluorescence intensities of all remaining PrP
particles were summed. We detected PrP aggregates in plasma samples from six out of ten scrapie-positive sheep with no
false positives from uninfected sheep. Applying simultaneous intensity and size discrimination, ten out of ten samples from
scrapie sheep could be differentiated from uninfected sheep. The implications for ante mortem diagnosis of prion diseases
are discussed.
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Introduction
Prion diseases are fatal neurodegenerative diseases in humans
and animals. Most prominent examples are scrapie in sheep,
bovine spongiform encephalopathy (BSE) in cattle, chronic
wasting disease in deer (CWD) and Creutzfeldt-Jakob disease
(CJD) in humans. A characteristic feature of prion diseases is the
accumulation of a pathological isoform of the host-encoded prion
protein (PrP). Whereas the cellular isoform, PrP
C, is soluble in
mild detergents, the pathological isoform, PrP
Sc, forms insoluble
aggregates. While PrP
C is highly sensitive to complete digestion
with proteinase K (PK), PrP
Sc is only N-terminally truncated
leaving the C-terminal part (aminoacids 90–231) undigested with
high retention of infectivity. Thus, PrP
Sc embodies both a PK-
resistant and a PK-sensitive portion; both moieties form aggre-
gates, and neither can be detected in uninfected animals or
humans. According to the prion hypothesis proposed by Stanley
Prusiner, PrP
Sc is, by itself, the agent of this class of transmissible
diseases [1]. The prion hypothesis has now been strongly
corroborated by recent demonstrations of infectivity in particles
prepared in vitro from recombinant PrP, though the PrP
conformation(s) bearing infectivity still has to be clarified [2–4].
As for any transmissible disease, sensitive and reliable diagnostic
procedures are obvious prerequisites to the control of transmission.
To control the BSE epidemic not only in Europe, but also in Japan
and Canada, an effective strategy of active monitoring is being
carried out through post mortem testing on cattle brain tissue. All of
these tests are based on detection of the PK-resistant forms of
PrP
Sc except for a single test that detects PrP
Sc aggregates captured
by an aggregate-specific ligand without PK digestion [5]. The BSE
epidemic is now largely contained. Approximately 200 cases of
variant CJD (vCJD) have shown, however, that BSE can cross the
species barrier to human. Unresolved problems include the lack of
sensitive live tests, incomplete knowledge of sources and routes of
exposure and transmission, and means to assess, monitor and
manage the public health risks from infected blood.
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like hamster [6,7] as well as in species naturally susceptible to
prion diseases like sheep and deer [8,9]. Moreover, some cases of
secondary variant Creutzfeldt Jakob disease (svCJD) have been
reported that were caused by blood transfusion from presymp-
tomatic vCJD patients [10,11]. Transfusion transmission occurs
despite the low concentration of prion infectivity in blood, ,10
infectious doses/ml in clinically affected rodents, or 7 to 9 orders
of magnitude less than the concentration in the brains of
symptomatic mice or hamsters [7]. Post mortem tests on brain
samples can be carried out with high sensitivity and reliability,
whereas qualitatively similar tests based on body fluids of afflicted
humans or animals have yet to be developed. Blood tests are,
however, highly desired for pathogenesis studies, blood transfusion
safety and CJD-therapy assessment.
In recent years significant progress has been made in the field of
prion diagnostics with the development of prion seeded amplifi-
cation technologies like protein misfolding cyclic amplification
(PMCA, [12]), quaking induced conversion (QuIC, [13]), and
amyloid seeding assay (ASA, [14]). QuIC was successfully applied
to cerebrospinal fluid samples from sporadic CJD patients [15,16]
and rodent blood [17]. Using PMCA, it has been possible to detect
PrP
Sc in blood from prion-infected hamsters, sheep and deer [18–
23]. At present, however, PMCA is carried out reliably, i.e.
without false positives, only in highly specialized laboratories. In
another development, PrP
Sc was detected in the peripheral
mononuclear blood cells (PBMC) of scrapie-afflicted sheep [24],
and in blood samples of variant CJD cases by an improved
immune detection method of surface-captured prions that did not
require the use of in vitro amplification and protease digestion [25].
In this study we have investigated PrP aggregates, PK-resistant
as well as PK-sensitive forms, in blood plasma of scrapie-infected
sheep. We have adapted our previously developed fluorescence
intensity distribution analysis (surface-FIDA) technique [26,27] for
analysis of blood samples of sheep. PrP aggregates are partially
purified from blood plasma, captured on a surface by covalently
bound antibodies and made visible by fluorophore-labeled
detection antibodies. The fluorescence emitted in response to a
scanning laser beam is transformed into an image of the PrP
fluorescence intensities on the surface. Several features of the
method, e.g. sample preparation, detection, and data processing,
guarantee that PrP aggregates can be differentiated safely from
PrP
C. We show that PrP aggregates are detectable in blood of
scrapie-infected sheep and that their presence indicates scrapie
infection.
Materials and Methods
Ethics Statement
All animal work was conducted in compliance with relevant
national guidelines. The sheep plasma reference pool was created
from blood collected in compliance with Institutional Animal Care
and Use Committee approved Protocol #2000-17 issued by the
University of Idaho. Animal procedures for gain of individual
blood samples were approved by the UK home office under the
Animals (Scientific Procedures) Act 1986.
Preparation of recombinant PrP aggregates
Bacterial expression and purification of recombinant (rec) ovine
PrP25–233 carrying the VRQ allele was performed as described
elsewhere [28]. Protein was stored in 10 mM sodium phosphate
buffer (NaPi) pH 7.2, supplemented with 0.2% sodium dodecyl
sulfate (SDS). Amorphous aggregates of recPrP were obtained by
reducing the SDS concentration in the monomer solution by
dilution of the recPrP stock solution to100 to 200 ng/ml PrP in
10 mM NaPi pH 7.2 followed by incubation at 37uC for 16 hours
[29]. Aggregation was monitored by ultracentrifugation at
100,000 g for 1 h followed by dot blot analysis of pellet and
supernatant.
Preparation of blood plasma
Blood was obtained from clinically-affected sheep (VRQ
homozygous) naturally infected with scrapie and control sheep
as described by Terry et al. [24]. Analyses of reproducibility were
performed on aliquots of a reference plasma (Rohwer Lab, Batch
101 Grade A hemoglobin OD575 nm=0.047) pooled from fresh
frozen plasma collected from 42 scrapie-infected North American
sheep of various breeds and genotypes. Sheep symptomatic with
scrapie were exsanguinated into CP2D via the jugular vein during
euthanasia under supervision of Dr. Marie Bulgin, at the Caine
Veterinary Teaching Center, 1020 E. Homedale Rd., Caldwell,
ID. 83607. Frozen plasma from 42 sheep were thawed at#four
degrees centigrade, and after reserving one or more 50 ml aliquots
of each plasma for future studies, the remainder was combined
and thoroughly but gently mixed before re-aliquoting and
refreezing at,=280C for storage.
Prior to Surface-FIDA analysis, plasma samples were thawed
slowly on ice and treated with Complete Protease Inhibitor
Cocktail (Roche, Mannheim, Germany). Gross debris was
removed by brief 5006g centrifugation. Samples were adjusted
to 2% (w/v) n-lauroylsarcosin (sarkosyl, Fluka Analytical, Buchs,
Switzerland) and incubated for 15 min at 37uC. Afterwards, lipids
and lipid moieties were digested by adding 1 ml Phospholipase C
from Clostridium perfringens (Sigma Aldrich, St. Louis, MO, USA),
1 ml Phospholipase A2 from porcine pancreas (Sigma Aldrich), and
1 ml Candida antarctica lipase B (CalB, Novozym 435, Novozymes,
Denmark) per 100 ml of blood plasma. Lipatic digestion was
conducted for 1 h at 37uC on a rocking platform. As a final step
PrP aggregates were concentrated by precipitation with 2% (w/v)
phosphotungstic acid (PTA, Sigma Aldrich). The mixture was
incubated for 1 h at 37uC and centrifuged for 30 min at 14.0006g
in a tabletop centrifuge. Pellets were resuspended using ultrasound
(30 sec, 170 W in a sonication bath).
Surface-FIDA assay
The microplates (SensoPlate Plus 384 well glass bottom
microplates, Greiner Bio One, Kremsmu ¨nster, Austria) consist of
a flat borosilicate glass bottom and a black polystyrene frame.
They are suitable for fluorescence measurements on the surface.
To bind the capture antibody covalently to the glass surface we
used the heterobifunctional polyethylene glycol spacer (NHS-
PEG-COOH, MW 3.400, Laysan Bio, Arab, AL, USA) according
to an optimized protocol for single molecule applications [30]. The
glass surface was cleaned consecutively with 100 ml of 5 M NaOH
and with 100 ml of 1 M HCl per well. It was rinsed with water and
ethanol and then dried in a nitrogen stream. The glass was next
immersed for 1 h in 50 mM PEG-spacer dissolved in dimethyl
sulfoxide containing 2% (v/v) triethylamine (Fluka, Basel, Swit-
zerland). After activation of the carboxylic end group of the spacer
by 50 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid and
50 mM N-Hydroxysuccinimide for 30 min, wells were washed
with 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 5.0.
To crosslink the capture antibody to the glass, 1 mg of mAB SAF-
32 (SPI-Bio, Montigny le Bretonneux, France), was added and
incubated for 1 h. Antibody mAB SAF-32 binds to the octarepeat
region located in the N-terminus of PrP. Unbound antibody was
removed by washing three times with phosphate buffered saline
(PBS). Finally 3% (w/v) bovine serum albumin containing 30 mM
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activated carboxylic end groups of the PEG-spacer. Before
addition of the target, the wells of the microplate were washed 4
times with PBST (PBS, 0.2% Tween20) and 3 times with PBS.
The resuspended PTA pellets from the plasma preparations
were added to the wells and incubated at 4uC for 16 h (optionally
for 1 h at room temperature); unbound protein was removed from
the captured aggregates by washing with PBST and PBS. For
fluorescence detection 20 ml of 2.5 ng/ml Alexa-488 conjugated
detection antibody SAF-32 or Alexa-633 conjugated antibody L42
were applied to each well and incubated for 1 h at ambient
temperature. Unbound detection antibody was removed followed
by three washing steps with PBST and three washing steps with
PBS. Analysis of the samples was performed on the same day.
The device employed for surface-FIDA is a customized
fluorescence correlation spectrometer (FCS Olympus IX 50,
Evotec, Hamburg Germany). For surface imaging the instrument
was upgraded with a MIPSS module (Modular Imaging and
Photon Statistics System, Ionovation, Osnabru ¨ck, Germany). The
scanning unit includes a 625 mrad tilt mirror installed on a 2D
piezo element, which is capable of scanning an image in the
confocal plane. The emission of the fluorescent antibody probes is
collected by high-sensitivity avalanche photo diodes, suitable for
single molecule spectroscopy. Intensity binary data are collected
and finally transformed into 16 bit images in tagged image file
format (TIFF).
Prior to scanning, the laser is focused on the glass surface.
Typically, for each well four to nine images each of
200 mm6200 mm were recorded at a resolution of 330 to
500 nm per pixel. For data evaluation the open source ImageJ
tool was used (available at http://rsb.info.nih.gov/ij; developed by
Wayne Rasband, National Institutes of Health, Bethesda, MD).
Background reduction
The ‘‘subtract background’’ function in the ImageJ software
employs the ‘rolling ball’ algorithm [31]. This algorithm not only
compensates for uneven intensity distributions within an individual
image, but is also capable of selecting for particular particle sizes.
The image data can be visualized as a 2D surface with the pixel
intensity as the third dimension. As shown schematically in Fig. 1
for a one-dimensional scan of the surface, a ball of a particular
radius, selected as a parameter, is rolled along the underside of the
surface. The ball can invade peaks of larger width but not those of
smaller size. It thereby creates a local background distribution.
Regions where the ball can go are subtracted from the image. As a
general rule, the smaller the ball radius, the more background is
removed. Narrow peaks of low intensities, which persist after
‘rolling ball’ processing, are subsequently removed by applying an
intensity cut-off. For this purpose, a fixed value is subtracted from
each pixel’s intensity. Finally the remaining intensities of a sample
are summed and displayed as a bar chart.
Results
Recovery of artificial PrP aggregates from plasma
samples
Although surface-FIDA is sensitive enough to detect and
quantify PrP aggregates at the single particle level, the sensitivity
and reliability of the assay depends on the accessibility of PrP
aggregate epitopes to the capture and detection antibodies. The
conditions for preparation of plasma were optimized using
aggregates of recombinant PrP. When 50 ng of preformed
amorphous recPrP aggregates were added to 100 ml PBS buffer
and the same amount was spiked into 100 ml EDTA plasma of
sheep and analysed by surface-FIDA, very few PrP aggregates
were detectable in PrP-spiked blood plasma compared to buffer
(Figs. 2A, 2B). Safar and colleagues [32] reported that human
prions are associated with low density lipoprotein (LDL and
VLDL). Hence, we postulated that recPrP aggregates may also
associate with these lipoproteins and other lipid particles when
added to plasma thereby masking the epitopes available for
capture and detection by antibodies. We therefore devised a
strategy to expose the epitopes on recPrP aggregates by combining
a detergent solubilization step with subsequent enzymatic hydro-
lysis of lipids. To disperse LDL-PrP complexes the spiked plasma
samples were treated with 2% (w/v) n-lauroylsarcosin (sarkosyl)
resulting in a moderate increase of detectable aggregates (barely
visible in Fig. 2C). Detergent-solubilized samples were subse-
quently incubated with a mixture of phospholipase A, phospho-
lipase C, and CalB lipase. This treatment significantly increased
the amount of detectable aggregates (Fig. 2D). Finally, PrP
aggregates were enriched by precipitation with PTA (Fig. 2E).
Direct precipitation of spiked plasma without prior enzymatic
treatment resulted in formless, diffuse signals (Fig. 2F), whereas
lipolyzed plasma without PrP yielded very low background
(Fig. 2G).
Detection and quantitation of authentic PrP aggregates
in natural blood samples
Once conditions for aggregate detection had been established,
plasma pools prepared from uninfected and scrapie-affected sheep
were assayed. In order to assess the reproducibility of the surface
FIDA assay, we analyzed replicate samples from these plasma
pools. Sample preparation was conducted independently by two
experimenters to estimate operator error. For each sample, the
PTA pellet was resuspended and then divided equally between two
wells. After background reduction by intensity cut-off application,
Figure 1. Schematic representation of the intensity distribution
by an one-dimensional scan through the surface. A ‘rolling ball’
moves along (arrow) the underside of the intensity curve and thereby
identifies the background, which is subsequently subtracted. Remaining
peaks of low intensities are removed by an intensity cut-off (dashed
line). In the algorithm, the ball moves along a three-dimensional
landscape, identifying peaks with a two-dimensional bottom and the
intensity as the third dimension.
doi:10.1371/journal.pone.0036620.g001
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comparisons between samples.
Preparation and measurement of the samples were performed
over several days. Because factors like daily device calibration,
brightness of fluorescent antibodies, variations in laser power, etc.
have large impacts on absolute intensities, the fluorescence signals
were normalized. Normalization provides a more easily interpret-
able discrimination between negative and positive samples.
Normalization was performed by subtracting intensities of the
negative control samples that were processed with the positive
samples from the intensities of the positive samples (Ipos2Ineg).
This difference was then divided by the intensity of the positive
sample (Ipos2Ineg)/Ipos. A value of 1, achievable only if the
background is zero, reflects the maximum possible discrimination
from background, a value close or below zero means no
differentiation.
Results of this evaluation are depicted in Fig. 3. In the majority
of the measurements the positive samples yielded more than a
tenfold higher fluorescence intensity compared to the negative
sample (discriminability .0.9). In only two out nine measurements
was discriminability lower, 0.49 and 0.67. Since the samples were
identical, these differences are apparently due to procedural
variability which should be amenable to reduction. Even for these
samples the discrimination was unambiguous i.e. the fluorescence
from the positive sample was still higher than background by a
factor of 2 and 3, respectively. Taken together, surface-FIDA is
able to discriminate positive from negative plasma samples in a
reproducible manner.
Detection of PrP aggregates in individual blood samples
We prepared and analyzed blood plasma from individual
scrapie-infected sheep and healthy control sheep as described
above. Samples were blinded before preparation and data
evaluation. Images were subjected to background reduction
(‘rolling ball’ radius=10 px., cut-off=200) as described in the
method section, and the remaining intensities were summed and
plotted as single values in Figure 4. A threshold value that clearly
separated stronger from weaker signals was assigned. Samples with
intensities well above the indicated threshold value (dashed line,
Fig. 4) were classified as positive. After unblinding the samples by
our colleagues at the AHVLA (Weybridge), we observed that 6 out
of 10 scrapie-positive clinical animals had been identified as
positive without any false-positives.
Optimization of background removal
The cutoff and threshold values assigned to the blinded samples
were by necessity somewhat arbitrary. Once sample identity had
been disclosed, background reduction parameters could be
optimized in order to maximize signal-to-noise from the FIDA
analysis. Optimizations were performed on two exceptionally
critical samples: Negative sample no. 6 yielded the highest
intensity among all controls, while positive sample no. 7 showed
the lowest signal among all clinical samples (Fig. 4). Both samples
show an uneven background, the control even higher than the
positive sample. In the control fairly large particles are visible, in
the positive sample significantly smaller particles (Fig. 5A). The
radius of the ‘rolling ball’ was varied from 1 to 10 px, followed by
an intensity cut-off of 500 (Fig. 5B). Remarkably, differentiation of
the negative and the positive sample was achieved at radii of 1 and
2 px (corresponding to 500 and 1000 nm). Moreover with these
parameters all ten samples from scrapie-affected sheep were
differentiated from uninfected control sheep (Fig. 5C). Therefore,
it is the small but highly intense particles that best discriminate
scrapie infected from uninfected plasma and must also therefore be
disease-specific.
Discussion
Methodological aspects
The method of surface-FIDA was developed earlier [26] and in
the present work has been applied to analyze authentic PrP
aggregates in blood of sheep. It was the intention of this study, first
to detect and characterize PrP particles in blood and second to
determine if surface-FIDA would be appropriate for a live test for
scrapie infection in individual sheep. The sensitivity was expected
to be higher compared to ELISA, even though in both methods
Figure 2. Detection of recPrP particles in the presence of blood plasma. To better resolve grayscales, images are colorized with ‘fire’ lookup
table (cf. right bar). Each sample contained 50 ng recPrP aggregates in 100 ml sample volume. All samples were analyzed by surface-FIDA assay using
SAF-32 as capture and detection antibody. One image corresponds to 1% of the total well bottom area. RecPrP aggregates (A) in PBS, (B) in ovine
plasma, (C) in plasma and 2% sarkosyl, (D) in plasma after sarkosyl and lipase treatment, (E) in plasma after sarkosyl and lipase treatment and PTA-
precipitation, (F) in plasma after PTA precipitation. (G) negative control: non-spiked plasma after sarkosyl, lipase and PTA steps.
doi:10.1371/journal.pone.0036620.g002
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FIDA individual particles are discriminated from their neighbor-
ing background, whereas in ELISA an integrated signal of the
whole surface is obtained and compared to the integrated signal
from a control sample. Recently, Terry et al. [24] reported an
improved ELISA test, in which the authors detected PrP
Sc in
PBMCs from 55% of scrapie-infected sheep in a blind panel. The
blood plasma samples tested in our study were derived from the
blood panel used to produce the corresponding cellular samples
tested by Terry and colleagues. A comparison of the results
showed that both assays had a total sensitivity of 55–60%, and
both detected the same 60% of positive cases. It should be noted,
however, that infectivity in the PBMC fraction is about one order
of magnitude higher compared to blood plasma [6,7], and prions
were not detected in plasma by the ELISA method reported by
Terry et al.
In an earlier study, we described the detection of PrP aggregates
with high sensitivity in brain homogenate of BSE cattle, and in a
small number of cerebrospinal fluid samples from BSE cattle [26].
According to the literature, infectivity in blood - even in
symptomatic experimental hamsters - is as low as 10 infectious
units per ml [33,34]. In BSE-afflicted cattle infectivity is absent
from the lymphatic system and has never been reported in blood
[35,36]. However, seeding activity was demonstrated in a small
number of BSE serum samples [37]. Considerable effort was spent
not only in improving the sensitivity of the assay but also in
optimizing the preparation of PrP aggregates from blood plasma.
Though it is not certain that the PrP aggregates we analyzed are
indeed the carriers of infectivity in blood, they are a consistent
marker of infection. The direct determination of infectivity in these
PrP aggregates from blood remains to be established.
Although PrP particle number was expected to be very small in
blood plasma, it is clear from our data that PrP aggregates are not
only associated with cells, like peripheral mononuclear blood cells
prepared from buffy coat, but are also present in plasma. A PK-
digestion step was avoided because it had been shown earlier that
some portion of PrP aggregates is PK-sensitive. Spiking of blood
plasma with PrP
Sc from brain for method development was not
successful in our hands, because the properties of PrP
Sc-samples
from brain proved to be very different from those of the genuine
PrP aggregates in blood. Recombinant polymorphous PrP
aggregates behaved more suitably as spiking material because
they remained stable in plasma and allowed us to develop
procedures to overcome epitope masking for antibody binding. We
Figure 3. Reproducibility of plasma analyses. Replicate samples of a plasma pool prepared from sheep symptomatic for scrapie and from a
pool prepared from uninfected control sheep were processed independently by two experimenters (A and B). Discriminability of positive and
negative samples is expressed as fluorescence intensity (positive, p) minus intensity (negative, n) divided by intensity (positive, p). MAb SAF-32 was
used as capture, mAb L42 as probe.
doi:10.1371/journal.pone.0036620.g003
Figure 4. Detection of PrP particles in blood plasma of scrapie-
infected sheep in a blinded study. PrP aggregates from 15 plasma
samples were prepared, applied to surface-FIDA using mAb SAF-32 as
capture and detection probe and evaluated using a rolling ball radius of
10 px. and intensity cut-off 200. After decoding samples were assigned
as scrapie-positive (red) or uninfected controls (green).
doi:10.1371/journal.pone.0036620.g004
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lipoproteins and lipids as described by Safar and colleagues [32]
and the epitopes were unmasked successfully by treatment with a
mild detergent and a lipase cocktail. Finally, precipitation with
PTA under optimized conditions was effective in concentrating the
few PrP aggregates in blood plasma.
MAb SAF-32 was used both for capture and detection in the
serial measurements (Fig. 4), although mAb L42 could also be
successfully applied as probe (Fig. 3). SAF-32 has the advantage of
more epitopes in the octarepeat region, resulting in higher
sensitivity. A disadvantage, however, could be that SAF-32
epitopes are not present anymore in PrP27–30, i.e. after
truncation at amino acid 89/90. In order to increase the sensitivity
of PrP aggregate analysis, background signals had to be
suppressed. The antibodies used for capture as well as detection
may bind non-specifically to cell fractions and other non-PrP
compounds in the sample. We tried to solve this problem by using
two different detection probes simultaneously in dual-wavelength
mode differentiating specific and background signals by co-
localization. Unfortunately, non-specific antibody binding oc-
curred with different antibodies in a similar manner, possibly
mediated by the conserved region. Thus, background could not be
suppressed further by means of dual-color measurements. Use of a
different set of antibodies might overcome this problem. More-
over, additional probes like amyloid binding dyes or antibodies
directed against PrP
Sc [38,39] might further increase specificity.
Figure 5. Optimized image processing and evaluation. (A) Image raw data of control sample no. 6 (top) and a scrapie-positive sample no. 7
(bottom). Depicted is one representative out of nine images taken for each sample. Scale bar=50 mm. (B) Optimization of ‘rolling ball’ radius. After
applying rolling ball background subtraction an intensity cutoff (500) was applied. Smaller radii of 1 and 2 pixels (arrows) allow for differentiation of
the positive and the control sample (negative). (C) Optimized background removal parameters were applied to the complete panel of samples.
doi:10.1371/journal.pone.0036620.g005
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PrP aggregates have been detected unequivocally in blood
plasma of scrapie-infected sheep. The sum of the fluorescence
intensities of all particles in one well is more than an order of
magnitude over background in some animals; in other animals it
is, however, close to the corresponding signal from non-infected
animals. All blinded samples which were assigned as positive, were
indeed positive after unblinding; no false-positives were among the
controls. The variability in the signals from scrapie positive
animals might be a consequence of the variable extent of infection
or dissemination via the blood plasma. However, some variability
from our preparation and measurements cannot be excluded. The
handling of small, nearly invisible pellets from the PTA precipition
was critical and an erroneous result could be due to a loss of
otherwise detectable PrP aggregates at that step. A detailed
analysis of experimental errors was carried out with replicate
determinations on standardized plasma pools prepared from
scrapie and control sheep (cf. Fig. 4).
When we analyzed the blinded series of samples, we selected an
assay threshold which clearly separated a number of larger signals
from lesser signals regarded as background (Fig. 5A). After
decoding we had identified 60 to 70% of the positive samples with
no false positive samples. Once the infection status of all samples
was known we found that a rolling ball correction with a radius of
2 pixel and cut-off of 500 intensity units could discriminate 100%
of the positive samples from the negative samples (cf. Fig. 5B). By
using a 2 pixel background selection, only particles with a radius
smaller than 2 pixel, i.e. 660 nm were counted as PrP aggregates.
By specifying a high intensity cut-off of 500 fluorescence units only
bright particles were counted. We cannot exclude the existence of
larger PrP aggregates in blood, but they could not be differentiated
from the background. The best correlation between disease and
PrP aggregates in plasma was clearly achieved by filtering small
and bright aggregates.
At least two factors contribute to the size distribution of the PrP
aggregates: the genuine in vivo size distribution and the break-down
of larger aggregates by the ultrasonication step during the
preparation from plasma.
We estimate a particle size for the aggregates selected for
discrimination in Figure 5B of about a micrometer, after
subtracting 50 to 100 nm for the size of the fluorescent antibody
label. Particle sizes in the literature were derived from nanofiltra-
tion studies investigating the removal of infectivity from blood or
plasma. Summarizing the studies applying different filters,
preparation procedures and solution conditions lower limits of
the particle sizes between 15 and 200 nm were estimated [40–
47].Thus the lower limit found in filtration experiments and the
upper limit reported here do not contradict each other. Sonication
can affect PrP aggregate size, but does not break down the
aggregates below the size of infectious particles. A rough
estimation of the number of PrP molecules in PrP aggregates as
observed in plasma leads to 10
5 to 10
6 molecules, which
corresponds to an earlier estimation of PrP molecules per
infectious unit in brain [48]. While our estimates of particle size
are derived from natural PrP aggregates in plasma, it must be
pointed out that all of the precedent filtration studies on plasma
have, by necessity, employed brain or spleen derived tissue
homogenates as a source of PrP
Sc and infectivity. This is because
there has not been an assay sensitive enough to detect disease-
specific PrP in blood. This is the first direct measurement of the
size of endogenous disease-specific PrP aggregates in plasma. It
should be noted that particular, detergent-including preparation of
infectious particles from brain led to determination of smaller
infectious units [49].
Surface-FIDA for live test
This study has demonstrated that disease-specific PrP aggre-
gates can be detected in blood plasma. As a consequence, the
method employed, surface-FIDA, could appropriately be used to
test living sheep for scrapie infection. So far we have only tested
symptomatic sheep. With a signal over background ratio of over
ten for symptomatic animals, it is likely that the assay can also be
extended to sheep in the preclinical stage. Refinements of
concentration, detection modalities, and instrumentation may
further extend the sensitivity. A self-modified fluorescence
correlation spectrometer was used for the measurements presented
here. In the meantime autofocussing laser scanning microscopes
with a high degree of automation have appeared on the market
which should improve the quality of the analysis. Labeling with
two different antibodies did not significantly improve the analysis
in the present work but might be applied more successfully in the
future using different antibodies e.g. one sequence specific and one
structure specific antibody, or by using fibril-specific dyes like
Thioflavin T as a second probe. QuIC and PMCA are probably
the more sensitive tests. Surface-FIDA has the potential to be
much faster than PMCA and may be more amenable to high
throughput. Because amplification technologies and surface-FIDA
rely on different properties of the infectivity, i.e. seeding activity
versus presence of PrP particles, the two assays complement each
other as valuable cross-confirmatory tests. Surface-FIDA might be
used in combination with QuIC or PMCA to further increase
sensitivity or speed of that assay.
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